Cboe Q3 2026 slides: S&P deal secured, earnings beat estimates

Cboe reported Q3 2026 adjusted EPS of $3.63 versus $3.42 consensus and revenue of $712.2 million versus $707.3 million, with adjusted EBITDA up 28% to $521.8 million and a record 73.3% margin. It extended its exclusive S&P index-products license through 2051 and raised full-year organic revenue growth guidance to high teens; shares rose 6.77% to $335.53. The company also raised its dividend to $0.86 per share and authorized an additional $550 million in buybacks.

Analysis

CBOE’s strongest earnings signal is not the quarter’s volume spike but evidence that incremental activity is converting into unusually high operating leverage. If that persists, recurring market-data and connectivity growth may support a more durable earnings base than 0DTE transaction revenue alone. The key distinction for valuation is whether data demand and access fees keep compounding when volatility and retail trading activity normalize.

The S&P license extension reduces a major franchise-renewal risk, but does not remove economics risk: updated royalties begin in 2027, and “de minimis” net impact is management’s claim, not yet independently demonstrated. A sustained rise in 0DTE also concentrates exposure to retail behavior, volatility regimes, and potential scrutiny of short-dated options. Any regulatory or broker-level restrictions could pressure volumes and weaken the growth narrative; conversely, broader distribution through Interactive Brokers (IBKR) and Charles Schwab (SCHW) could reinforce liquidity and data demand. Cboe’s KPI event contracts are an option on new retail engagement, but launch approvals and brokerage access do not establish meaningful economics.

Near term, the 6.77% post-results jump raises the risk of chasing a strong print. Over 1–3 months, watch realized options volumes, data growth, and year-end product launches. Over 6–18 months, the test is whether 2027 royalty costs are absorbed without sacrificing growth or margins. The article also reports options revenue above derivatives net revenue; these figures may use different scopes, but require verification against the filing before underwriting segment economics.

Key Decisions for Investors

• Do not chase the immediate gap. Consider CBOE on consolidation or a pullback, with position sizing tied to the risk that 0DTE volumes normalize; reassess if subsequent results show weaker transaction revenue or margin conversion.
• Treat CBOE’s data-and-connectivity business as the higher-quality part of the thesis. Monitor organic Data Vantage growth and access/capacity fees; a material slowdown would weaken the case that earnings growth is less dependent on trading activity.
• Track the 2027 S&P royalty terms and management’s February 2027 guidance. Falsification: royalty costs or other expenses materially constrain net revenue growth or operating margins despite continued volume growth.
• Keep KPI event contracts on a watchlist rather than valuing them as an established growth driver. Verify launch, sustained liquidity, customer participation, and economics after the fee holiday; regulatory changes or limited adoption would undermine the option value.
• Before relying on segment growth claims, reconcile the reported options revenue and derivatives net revenue figures with Cboe’s original filing; do not build a segment forecast from potentially inconsistent scopes.